Meeting
2022 ASCO Annual Meeting
Four-year follow-up from a phase 2 study of obinutuzumab, ibrutinib, and venetoclax in CLL.
Authors
Kerry Anne Rogers
Division of Hematology, The Ohio State University, Columbus, OH
Kerry Anne Rogers , Ying Huang , Lynne Abruzzo , Seema Ali Bhat , Tzyy-Jye Doong , Adam Kittai , Arletta Lozanski , Gerard Lozanski , Margaret Lucas , Kami J. Maddocks , Charelen Mao , Megan Nussbaum , Ellen J Sass , Swetha Suresh , John C. Byrd , Jennifer Ann Woyach
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT02427451
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7540)
DOI
10.1200/JCO.2022.40.16_suppl.7540
Abstract #
7540
Poster Bd #
193
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia.
First Author: Von Tresckow Julia
Poster
2017 ASCO Annual Meeting
Cytogenetic and fluorescence in situ hybridization testing in veterans with chronic lymphocytic leukemia.
First Author: Ahmad Sami Halwani
Poster
2023 ASCO Annual Meeting
Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.
First Author: Paul M. Barr
Poster
2020 ASCO Virtual Scientific Program
Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.
First Author: Othman Al-Sawaf